|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Hepatocellular cancer
Datamonitor, Dec 2010, Pages: 126
Despite the approval of Nexavar (sorafenib; Onyx pharmaceuticals/Bayer), patient outcomes remain poor. The large patient population and the lack of effective agents are driving R&D interest. The majority of pipeline drugs are molecular targeted therapies (MTTs) and their incorporation into treatment will improve both patient outcomes and commercial potential.
Scope of this research:
- Hepatocellular cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential
- Discussion of current treatment options for hepatocellular cancer and their limitations
- Examination of the late-phase hepatocellular cancer pipeline, including drug profiles of late-stage agents
- Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and Japan
Research and analysis highlights:
Hepatocellular cancer (HCC) is the fifth and seventh most common cancer in men and women respectively. The majority of patients with HCC are diagnosed with advanced-stage disease and have existing liver damage. The only approved treatment for late-stage disease is Nexavar which is not curative.
Chemotherapy is rarely used in hepatocellular cancer (HCC) as it is associated with low response rates. Regional therapies for early-stage patients have a high exclusion criteria and curative surgery is associated with relapse rates as high as 21.8%. Novel therapies are needed to improve survival rates in both early and late stage disease
There are currently 67 drugs in the pipeline, which is dominated by molecular targeted therapies (71%) and cytotoxic therapies (18%). Competition of late-phase pipeline drugs for first approval in HCC is fierce.
Key reasons to purchase this research
- Estimate the number of treatable patients and identify unmet needs for future drug development opportunities
- Understand the current treatment of the disease, as well as opportunities and threats in the hepatocellular cancer market
- Analyze the current hepatocellular cancer pipeline and the potential of late-stage drugs
|
|
|
|
